In an AMP Global presentation, Danish Cancer Society Research Center scientists used the test to study urine samples from individuals who developed bladder cancer up to 15 years later.
In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.
A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.
In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.
Paradigm will use its NGS-based PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib.
Cancer Genetics CEO Panna Sharma told GenomeWeb this week that the company plans to focus on very targeted panels of actionable mutations.
Researchers from the MD Anderson Cancer Center this month reported new data showing that the microRNA-200 family, which has previously been implicated in cancer metastasis, can regulate tumor angiogenesis.
NEW YORK (GenomeWeb News) – 23andMe today announced the expansion of its online study conducted with Genentech for the biotech firm's oncology drug Avastin (bevacizumab).
The companies' first project will be a renal cancer clinical trial for an undisclosed Quintiles client. The partners aim to identify genetic markers that are predictive of adverse events and efficacy.
Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.